ClinicalTrials.gg
Active, not recruitingNCT05775159Updated Aug 24, 2026

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

A Phase 2 interventional study of Volrustomig and Bevacizumab in Hepatocellular Carcinoma and Biliary Tract Cancer, sponsored by AstraZeneca. Active, not recruiting at 46 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
294
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing bevacizumab in Carcinoma, Hepatocellular — 27 open to participants now, 37 under way, 5 of them phase 3. Bevacizumab · Carcinoma, Hepatocellular.

Planned enrollment
10th of 73
294 · median 45
Started
2023
with 10 others
Phase 2
40 of 73
13 open now
Primary completion
2026-10
later than 12 of 36 live
Registered
47th of 73
by date
Lead sponsor
4 of 73
AstraZeneca

Among the 73 studies testing bevacizumab in Carcinoma, Hepatocellular, this one is the 10th largest by planned enrollment, is one of 11 that started in 2023, is one of 40 in phase 2, reaches primary completion later than 12 of the 36 other live ones, and was the 47th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

27 of the 73 studies testing bevacizumab in Carcinoma, Hepatocellular are open now, in 11 countries. Recruiting first, the newest first:

22 more — sign in →

By country, each count listing its studies:

All 27 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing bevacizumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.

Read the detailed description

This Phase II, open-label, uncontrolled, multicentre study evaluating the preliminary efficacy and safety of Volrustomig or Rilvegostomig as monotherapy (MONO) and/or in combination with anticancer agents (COMBO) in participants with advanced hepatobiliary cancer (e.g., HCC, BTC, etc.).

This study has a modular design with independent substudies. In Substudy 1, Volrustomig and Rilvegostomig will be evaluated as monotherapy and/or in combination with other anticancer drugs in approximately 200 evaluable participants with advanced HCC.

In Substudy 2, the efficacy and safety of Rilvegostomig or Volrustomig plus gemcitabine and cisplatin are investigated in approximately 90 evaluable participants with advanced BTC who have not received previous treatment for advanced/metastatic disease.

03

Conditions studied

  • Hepatocellular Carcinoma
  • Biliary Tract Cancer

Keywords

  • Hepatobiliary cancer
  • Hepatocellular carcinoma
  • Biliary tract cancer
  • GEMINI-Hepatobiliary
  • MEDI5752
  • AZD2936
  • Bispecific antibody
  • Volrustomig
  • Rilvegostomig
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years at the time of signing the ICF.
  • Provision of a signed and dated written ICF.
  • Confirmed locally advanced or solid tumor specified in substudy based on histopathology.
  • Adequate organ and bone marrow function.
  • At least 1 measurable not previously irradiated lesion per 1.1
  • of at least 12 weeks at the time of screening.
  • Willing and able to provide an adequate tumor sample.

Exclusion criteria

Exclusion Criteria:

  • History of allogeneic organ transplantation.
  • Active or prior documented or inflammatory disorders.
  • Uncontrolled intercurrent illness.
  • History of another primary , , and active primary immunodeficiency.
  • Active infection, or spinal cord compression.
  • Participants co-infected with and hepatitis D virus (HDV).
  • Previous treatment in the present study.
  • For substudy 1, history of hepatic encephalopathy within 12 months prior to treatment allocation.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
294 participants (estimated)

Study arms

  • Experimental
    Cohort 1A

    Volrustomig monotherapy

    Drug: Volrustomig

  • Experimental
    Cohort 1B

    Volrustomig combination with bevacizumab

    Drug: Volrustomig · Drug: Bevacizumab

  • Experimental
    Cohort 1C

    Volrustomig combination with lenvatinib

    Drug: Volrustomig · Drug: Lenvatinib

  • Experimental
    Cohort 2A

    Rilvegostomig combination with Gemcitabine and Cisplatin

    Drug: Rilvegostomig · Drug: Gemcitabine · Drug: Cisplatin

  • Experimental
    Cohort 2B

    Volrustomig combination with Gemcitabine and Cisplatin

    Drug: Volrustomig · Drug: Gemcitabine · Drug: Cisplatin

  • Experimental
    Cohort 1D

    Volrustomig combination with rilvegostomig and bevacizumab

    Drug: Volrustomig · Drug: Bevacizumab · Drug: Rilvegostomig

  • Experimental
    Cohort 1E

    Rilvegostomig combination with bevacizumab

    Drug: Bevacizumab · Drug: Rilvegostomig

Interventions

  • CTLA-4/Anti-PD-1 Bispecific Antibody

  • 15 mg/kg, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

  • Daily use per oral (8 mg capsules/day for participants \< 60 kg or 12 mg/day for participants ≥ 60 kg) of 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

  • anti- PD-1 and TIGIT bispecific antibody

  • 1000 mg/m2, IV infusion

  • 25 mg/m2, IV infusion

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    ORR is defined as the proportion of participants who have a confirmed CR (complete response) or confirmed PR (partial response), determined by the Investigator at local site per RECIST 1.1 (For HCC sub-study 1)

    Time frame: Through study completion, an average of 2 years

  2. The number of participants with adverse events/serious adverse events

    Number of participants with adverse events and with serious adverse events including abnormal clinical observations, abnormal Electrocardiogram (ECG) parameters, abnormal laboratory assessments and abnormal vital signs that changed from baseline.

    Time frame: Through study completion, an average of 2 years

  3. Progression free survival (PFS)

    PFS is defined as the time from the start of studyintervention until progression per RECIST 1.1 as assessed by the Investigator at the local site or death due to any cause in the absence of progression, whichever occurs first. (For BTC sub-study 2)

    Time frame: Through study completion, an average of 2 years

Secondary outcomes

  1. Duration Of Response (DOR)

    DoR is defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1 by the Investigator at local site or death due to any cause in the absence of disease progression, whichever occurs first.

    Time frame: Through study completion, an average of 2 years

  2. Disease Control Rate (DCR)

    DCR at 12 and 24 weeks is defined as the percentage of participants who have a Complete response (CR) or Partial response (PR) in the first 13 and 25 weeks or who have Stable disease (SD) for at least 11 and 23 weeks after the date of first dose respectively, per RECIST 1.1 as assessed by the investigator at local site and derived from the raw tumour data.

    Time frame: At 12 and 24 weeks

  3. Progression free survival (PFS)

    PFS is defined as the time from the start of study intervention until progression per RECIST 1.1 as assessed by the Investigator at the local site or death due to any cause in the absence of progression, whichever occurs first.

    Time frame: Through study completion, an average of 2 years

  4. Overall Survival (OS)

    OS is defined as the time from the start of study intervention until the date of death due to any cause, whichever occurs first.

    Time frame: Through study completion, an average of 2 years

  5. Anti Drug Antibody (ADA)

    Incidences of ADAs against novel immunomodulators in serum.

    Time frame: Through study completion, an average of 2 years

  6. Pharmacokinetics of novel immunomodulators: Maximum plasma concentration of the study drug (Cmax)

    Maximum observed plasma concentration of the study drug

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of novel immunomodulators ( approx 2 years )

  7. Pharmacokinetics of novel immunomodulators: Time to maximum plasma concentration of the study drug (T-max)

    Time to maximum observed plasma concentration of the study drug

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of novel immunomodulators ( approx 2 years )

  8. lmmunogenicity of novel immunomodulators

    The number and percentage of participants who develop ADAs.

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of novel immunomodulators ( approx 2 years)

  9. Objective response rate (ORR)

    ORR is defined as the proportion of participants who have a confirmed CR (complete response) or confirmed PR (partial response), determined by the Investigator at local site per RECIST 1.1

    Time frame: Through study completion, an average of 2 years

07

Study locations

46 sites
  • Research Site
    Birmingham, Alabama 35233, United States
  • Research Site
    Los Angeles, California 90089, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Kansas City, Kansas 66103, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Beijing, 100050, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Beijing, 101100, China
  • Research Site
    Chengdu, 610000, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chongqing, 400030, China
  • Research Site
    Fuzhou, 350007, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Guangzhou, 510515, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Nanning, 530021, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Hong Kong, 999077, Hong Kong
  • Research Site
    Shatin, 00000, Hong Kong
  • Research Site
    Florence, 50134, Italy
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Rozzano, 20089, Italy
  • Research Site
    Chūōku, 104-0045, Japan
  • Research Site
    Kashiwa, 277-8577, Japan
  • Research Site
    Yokohama, 241-8515, Japan
  • Research Site
    Seongnam-si, 463-712, South Korea
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 05505, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Barcelona, 08036, Spain
  • Research Site
    Barcelona, 8035, Spain
  • Research Site
    Madrid, 28007, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Pamplona, 31008, Spain
  • Research Site
    Kaohsiung City, 80756, Taiwan
  • Research Site
    Kaohsiung City, 833, Taiwan
  • Research Site
    Taichung, 407219, Taiwan
  • Research Site
    Tainan, 70403, Taiwan
  • Research Site
    Tainan, 710, Taiwan
  • Research Site
    Taipei, 10002, Taiwan
  • Research Site
    Taoyuan, 333, Taiwan
  • Research Site
    Cambridge, CB2 0QQ, United Kingdom
  • Research Site
    London, NW3 2QG, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Oct 2026, 42 months after the start.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's planned 42 months is above that.

Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2023
First posted
Mar 20, 2023
StartActual
Apr 24, 2023
Primary completionEst.
Oct 27, 2026
CompletionEst.
Oct 28, 2027
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05775159
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 20, 2023
Start date
Apr 24, 2023
Primary completion
Oct 27, 2026 (estimated)
Completion
Oct 28, 2027 (estimated)
Last update
Aug 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Volrustomig · Bevacizumab · Rilvegostomig · Gemcitabine · Cisplatin

Start the discussion